1: Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, Mendel CM, Egizi E, Moreira J, Timm J, McHugh TD, Wills GH, Bateson A, Hunt R, Van Niekerk C, Li M, Olugbosi M, Spigelman M; Nix-TB Trial Team. Treatment of Highly Drug- Resistant Pulmonary Tuberculosis. N Engl J Med. 2020 Mar 5;382(10):893-902. doi: 10.1056/NEJMoa1901814. PMID: 32130813; PMCID: PMC6955640.
2: Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012 Mar 1;54(5):621-9. doi: 10.1093/cid/cir895. Epub 2012 Jan 12. PMID: 22247123.
3: Chang M, Nguyen TT. Strategy for Treatment of Infected Diabetic Foot Ulcers. Acc Chem Res. 2021 Mar 2;54(5):1080-1093. doi: 10.1021/acs.accounts.0c00864. Epub 2021 Feb 17. PMID: 33596041.
4: Layer F, Weber RE, Fleige C, Strommenger B, Cuny C, Werner G. Excellent performance of CHROMagarTM LIN-R to selectively screen for linezolid- resistant enterococci and staphylococci. Diagn Microbiol Infect Dis. 2021 Apr;99(4):115301. doi: 10.1016/j.diagmicrobio.2020.115301. Epub 2020 Dec 29. PMID: 33444893.
5: Wen S, Zhang T, Yu X, Dong W, Lan T, Fan J, Xue Y, Wang F, Dong L, Qin S, Huang H. Bone penetration of linezolid in osteoarticular tuberculosis patients of China. Int J Infect Dis. 2021 Feb;103:364-369. doi: 10.1016/j.ijid.2020.11.203. Epub 2020 Dec 2. PMID: 33278623.
6: Morgon NH, Grandini GS, Yoguim MI, Porto CM, Santana LC, Biswas S, de Souza AR. Potential activity of Linezolid against SARS-CoV-2 using electronic and molecular docking study. J Mol Model. 2021 Jul 8;27(8):222. doi: 10.1007/s00894-021-04828-8. PMID: 34236527; PMCID: PMC8264178.
7: Peng Z, Nguyen TT, Song W, Anderson B, Wolter WR, Schroeder VA, Hesek D, Lee M, Mobashery S, Chang M. Selective MMP-9 Inhibitor (R)-ND-336 Alone or in Combination with Linezolid Accelerates Wound Healing in Infected Diabetic Mice. ACS Pharmacol Transl Sci. 2020 Sep 1;4(1):107-117. doi: 10.1021/acsptsci.0c00104. PMID: 33615165; PMCID: PMC7887744.
8: Souza E, Crass RL, Felton J, Hanaya K, Pai MP. Accumulation of Major Linezolid Metabolites in Patients with Renal Impairment. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e00027-20. doi: 10.1128/AAC.00027-20. PMID: 32152085; PMCID: PMC7179609.
9: Pittiruti M, Bertoglio S, Scoppettuolo G, Biffi R, Lamperti M, Dal Molin A, Panocchia N, Petrosillo N, Venditti M, Rigo C, DeLutio E. Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus. J Vasc Access. 2016 Nov 2;17(6):453-464. doi: 10.5301/jva.5000576. Epub 2016 Aug 1. PMID: 27516141.
10: Wang Y, Ye X, Lan Q, Ke X, Hu L, Hu L. UPLC-MS/MS Determination of Linezolid and Heme in Plasma of Infected Patients and Correlation Analysis. Biomed Res Int. 2021 Jul 10;2021:6679076. doi: 10.1155/2021/6679076. PMID: 34337043; PMCID: PMC8289587